Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Lonza Group AG | OTC Markets | Healthcare | Biotechnology & Medical Research | US$47.83B | 55x | 1.69 | US$67.66 | 1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 22.2% Upside | Upgrade to Pro+ | |
argenx ADR | NASDAQ | Healthcare | Biotechnology & Medical Research | US$39.49B | 30.5x | 0.05 | US$637.56 | -0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 24.3% Upside | Upgrade to Pro+ | |
BeOne Medicines DRC | NASDAQ | Healthcare | Biotechnology & Medical Research | US$31.70B | -179.4x | -2.68 | US$288.10 | -0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 21.5% Upside | Upgrade to Pro+ | |
IQVIA Holdings | NYSE | Healthcare | Biotechnology & Medical Research | US$31.60B | 26.6x | -2.43 | US$185.91 | 3.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 22.2% Upside | Upgrade to Pro+ | |
BioNTech | NASDAQ | Healthcare | Biotechnology & Medical Research | US$26.68B | -66.3x | -2.08 | US$111 | 1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 24.7% Upside | Upgrade to Pro+ | |
Insmed | NASDAQ | Healthcare | Biotechnology & Medical Research | US$25.79B | -21.1x | 4.82 | US$122 | 8.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -0.8% Downside | Upgrade to Pro+ | |
Summit Therapeutics PLC | NASDAQ | Healthcare | Biotechnology & Medical Research | US$19.08B | -83.2x | 0.83 | US$25.68 | -9.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 38.3% Upside | Upgrade to Pro+ | |
Wuxi Biologics | OTC Markets | Healthcare | Biotechnology & Medical Research | US$15.33B | 29.3x | 21.16 | US$7.61 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
WuXi Biologics | OTC Markets | Healthcare | Biotechnology & Medical Research | US$15.33B | 29.3x | 41.81 | US$3.85 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Genmab AS | NASDAQ | Healthcare | Biotechnology & Medical Research | US$13.32B | 10x | 0.12 | US$21.87 | 3.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 39.9% Upside | Upgrade to Pro+ | |
ICON PLC | NASDAQ | Healthcare | Biotechnology & Medical Research | US$13.15B | 17.2x | 1.19 | US$169.08 | 5.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 39% Upside | Upgrade to Pro+ | |
Medpace Holdings | NASDAQ | Healthcare | Biotechnology & Medical Research | US$12.90B | 33.1x | 1.14 | US$459.29 | 2.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -4.4% Downside | Upgrade to Pro+ | |
Ascendis Pharma AS | NASDAQ | Healthcare | Biotechnology & Medical Research | US$11.87B | -37x | -0.8 | US$195.98 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 27.2% Upside | Upgrade to Pro+ | |
Tempus AI | NASDAQ | Healthcare | Biotechnology & Medical Research | US$11.53B | -51.6x | -0.59 | US$66.34 | 9.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 5.5% Upside | Upgrade to Pro+ | |
Qiagen | NYSE | Healthcare | Biotechnology & Medical Research | US$10.62B | 28.5x | 0.07 | US$48.97 | 2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 9.4% Upside | Upgrade to Pro+ | |
Exelixis | NASDAQ | Healthcare | Biotechnology & Medical Research | US$10.22B | 17.5x | 0.2 | US$37.95 | 1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 20.3% Upside | Upgrade to Pro+ | |
Verona Pharma ADR | NASDAQ | Healthcare | Biotechnology & Medical Research | US$9.07B | -102.6x | -3.12 | US$105.19 | -0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 1.7% Upside | Upgrade to Pro+ | |
Bio-Techne | NASDAQ | Healthcare | Biotechnology & Medical Research | US$8.28B | 112.7x | -2.01 | US$52.83 | 5.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 23% Upside | Upgrade to Pro+ | |
Madrigal Pharma | NASDAQ | Healthcare | Biotechnology & Medical Research | US$8B | -27.9x | -0.55 | US$359 | 2.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 26.5% Upside | Upgrade to Pro+ | |
EXACT Sciences | NASDAQ | Healthcare | Biotechnology & Medical Research | US$7.90B | -7.7x | 0.02 | US$41.74 | 2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Charles River Laboratories | NYSE | Healthcare | Biotechnology & Medical Research | US$7.52B | -111.7x | 0.91 | US$152.75 | 2.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 14.1% Upside | Upgrade to Pro+ | |
Legend Bio | NASDAQ | Healthcare | Biotechnology & Medical Research | US$6.83B | -20.4x | -0.57 | US$36.99 | 2.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Regencell Bioscience Holdings | NASDAQ | Healthcare | Biotechnology & Medical Research | US$6.65B | -1,610x | US$13.44 | -0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Ionis Pharma | NASDAQ | Healthcare | Biotechnology & Medical Research | US$6.60B | -24x | -0.76 | US$41.41 | 1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 48.1% Upside | Upgrade to Pro+ | |
Revolution Med | NASDAQ | Healthcare | Biotechnology & Medical Research | US$6.59B | -7.8x | 0.31 | US$35.26 | 1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Nuvalent | NASDAQ | Healthcare | Biotechnology & Medical Research | US$5.52B | -15.7x | 0.21 | US$76.61 | 2.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 46.2% Upside | Upgrade to Pro+ | |
Abivax ADR | NASDAQ | Healthcare | Biotechnology & Medical Research | US$5.27B | -19.4x | -2.3 | US$71.91 | 4.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 36.3% Upside | Upgrade to Pro+ | |
Crispr Therapeutics | NASDAQ | Healthcare | Biotechnology & Medical Research | US$5.15B | -10.4x | 0.16 | US$56.60 | 2.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 44.4% Upside | Upgrade to Pro+ | |
Merus | NASDAQ | Healthcare | Biotechnology & Medical Research | US$4.82B | -11.4x | 0.14 | US$63.77 | -1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 44.3% Upside | Upgrade to Pro+ | |
Alkermes Plc | NASDAQ | Healthcare | Biotechnology & Medical Research | US$4.53B | 12.8x | 0.57 | US$27.43 | 3.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Viking Therapeutics Inc | NASDAQ | Healthcare | Biotechnology & Medical Research | US$4.48B | -25.9x | 0.39 | US$39.86 | 4.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Soleno Therapeutics | NASDAQ | Healthcare | Biotechnology & Medical Research | US$4.43B | -21.1x | 0.3 | US$83.36 | -2.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 37.6% Upside | Upgrade to Pro+ | |
ACADIA | NASDAQ | Healthcare | Biotechnology & Medical Research | US$4.29B | 19.3x | 0.03 | US$25.45 | 2.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 24.9% Upside | Upgrade to Pro+ | |
Krystal Biotech | NASDAQ | Healthcare | Biotechnology & Medical Research | US$4.16B | 28.1x | 0.78 | US$143.62 | 4.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 40% Upside | Upgrade to Pro+ | |
Cytokinetics Inc | NASDAQ | Healthcare | Biotechnology & Medical Research | US$4.11B | -6.8x | -1.52 | US$34.31 | 3.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Arcellx | NASDAQ | Healthcare | Biotechnology & Medical Research | US$4.02B | -20.6x | 0.09 | US$72.52 | 4.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Vaxcyte | NASDAQ | Healthcare | Biotechnology & Medical Research | US$3.89B | -7.3x | -0.7 | US$30 | 1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Akero Therapeutics | NASDAQ | Healthcare | Biotechnology & Medical Research | US$3.84B | -12.8x | 1.23 | US$48.03 | -0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Ascentage Pharma | NASDAQ | Healthcare | Biotechnology & Medical Research | US$3.71B | -30.1x | -1.11 | US$40.20 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -6.7% Downside | Upgrade to Pro+ | |
Telix Pharmaceuticals ADR | NASDAQ | Healthcare | Biotechnology & Medical Research | US$3.69B | 190.5x | 0.14 | US$10.82 | -0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
MoonLake Immunotherapeutics | NASDAQ | Healthcare | Biotechnology & Medical Research | US$3.48B | -19.5x | 0.09 | US$54.84 | 2.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 42.4% Upside | Upgrade to Pro+ | |
Protagonist Therapeutics | NASDAQ | Healthcare | Biotechnology & Medical Research | US$3.39B | 66.8x | -0.91 | US$54.53 | 1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 30.2% Upside | Upgrade to Pro+ | |
Metsera | NASDAQ | Healthcare | Biotechnology & Medical Research | US$3.24B | -6.3x | US$30.88 | 2.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Scholar Rock | NASDAQ | Healthcare | Biotechnology & Medical Research | US$3.10B | -9.8x | 0.34 | US$32.20 | 2.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Kymera | NASDAQ | Healthcare | Biotechnology & Medical Research | US$2.85B | -10.8x | 0.46 | US$39.87 | 5.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
NewAmsterdam Pharma | NASDAQ | Healthcare | Biotechnology & Medical Research | US$2.82B | -16x | -0.41 | US$25 | 2.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Xenon Pharmaceuticals | NASDAQ | Healthcare | Biotechnology & Medical Research | US$2.77B | -9.6x | 0.54 | US$35.99 | 5.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Alvotech | NASDAQ | Healthcare | Biotechnology & Medical Research | US$2.71B | 26.6x | 0.24 | US$8.65 | 1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Crinetics Pharma | NASDAQ | Healthcare | Biotechnology & Medical Research | US$2.68B | -6.9x | 0.74 | US$28.48 | 4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Immunovant | NASDAQ | Healthcare | Biotechnology & Medical Research | US$2.65B | -5.2x | 0.13 | US$15.21 | 3.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |